• Iptacopan (LNP023): Scientific Advances in Alternative Pathw

  2026-04-24

  Explore the advanced pharmacological, mechanistic, and translational insights of Iptacopan (LNP023), a potent inhibitor of the alternative complement pathway. This article delivers unique, evidence-backed guidance for researchers seeking to optimize complement-mediated hemolysis assays and animal disease models.

• Angiotensin 1/2 (1-6): Precision Hexapeptide for RAS Researc

  2026-04-23

  Angiotensin 1/2 (1-6) empowers researchers to dissect renin-angiotensin system signaling with unmatched precision. Its high solubility, purity, and well-characterized mechanism make it the gold standard for cardiovascular, renal, and emerging viral pathogenesis workflows.

• Macrophage-Driven Ferroptosis Governs Adipose Stem Cell Loss

  2026-04-23

  This study reveals how obesity-associated macrophages, through loss of TIPE2, induce ferroptosis in adipose stem cells (ASCs) by promoting mitochondrial fragmentation and iron overload. These findings uncover a novel macrophage-ASC crosstalk mechanism regulating visceral adipose tissue dysfunction, with implications for obesity-related metabolic diseases.

• Palonosetron Hydrochloride: Advancing Chemotherapy Antiemesi

  2026-04-22

  Ruhlmann & Herrstedt’s study systematically evaluates palonosetron hydrochloride’s unique pharmacological features and efficacy for preventing chemotherapy-induced nausea and vomiting (CINV). Their analysis highlights palonosetron’s superior prevention of delayed emesis and its clinical advantages over earlier 5-HT3 receptor antagonists, offering nuanced guidance for designing antiemetic regimens in oncology research.

• 6-Thioguanine: Mechanistic Leverage for Translational Innova

  2026-04-22

  This thought-leadership article explores the dual mechanistic action of 6-thioguanine in cancer and antiviral research, integrating recent literature on nanoparticle delivery, quantitative in vitro benchmarks, and translational strategies. It provides actionable protocol parameters, critically examines bioavailability challenges, and positions APExBIO’s Thioguanine as an indispensable research tool, while contextualizing its role within the competitive and clinical landscape.

• T7 RNA Polymerase in CRISPR gRNA Synthesis: Workflow, Eviden

  2026-04-21

  Explore the pivotal role of T7 RNA Polymerase, a recombinant enzyme expressed in E. coli, in high-fidelity gRNA and mRNA synthesis for gene editing and RNAi. Uniquely, this article dissects protocol nuances and real-world findings to empower advanced molecular assays.

• Minoxidil Sulphate in Vascular Biology: Protocols & Solution

  2026-04-21

  Minoxidil sulphate, the active metabolite of minoxidil, empowers high-fidelity research in hair growth and vascular biology by targeting potassium channels with precision. This guide details hands-on protocols, troubleshooting insights, and workflow strategies validated by recent experimental findings and APExBIO’s benchmark-grade compound.

• Artesunate: Advanced Workflows for In Vitro Cancer Research

  2026-04-20

  Artesunate, a potent artemisinin derivative, enables precise in vitro modeling of cancer signaling and cell death, especially in small cell lung and esophageal squamous cell carcinoma assays. This guide translates cutting-edge evidence and APExBIO’s product intelligence into actionable protocols and troubleshooting strategies for reproducible, data-driven oncology research.

• Morin: Advanced Mechanistic Insights and Translational Poten

  2026-04-20

  Explore the multifaceted mechanisms of Morin, a natural flavonoid, with unique insights into its modulation of cellular pathways and translational value in neuroprotection and disease modeling. This article provides an in-depth, evidence-driven analysis of Morin’s biochemical roles and practical guidance for research applications.

• Oligo (dT) 25 Beads: Precision Superparamagnetic mRNA Isolat

  2026-04-19

  Oligo (dT) 25 Beads leverage superparamagnetic technology for robust, high-fidelity eukaryotic mRNA isolation directly from complex biological samples. Optimized for polyA tail capture and streamlined workflow integration, these beads empower reproducible, high-yield applications from RT-PCR to next-generation sequencing.

• Chlorogenic Acid-Metal Assemblies: Enhanced Anti-Inflammator

  2026-04-18

  This study demonstrates that supramolecular assemblies of chlorogenic acids with iron and copper yield significantly improved anti-inflammatory efficacy via targeted inhibition of the NF-κB signaling pathway and downstream mediators. The findings present a novel strategy to augment natural product bioactivity, with translational implications for inflammation research and new agent development.

• Azithromycin: Macrolide Antibiotic Workflows in Resistance a

  2026-04-17

  Azithromycin empowers advanced bacterial infection and senescence studies with precise inhibition of protein synthesis and robust senolytic activity. This guide details experimental workflows, troubleshooting strategies, and protocol parameters, leveraging APExBIO's high-quality reagent for reproducible, high-impact research.

• Superoxide Dismutase (SOD) Activity Assay Kit: Technical Gui

  2026-04-16

  The Superoxide Dismutase (SOD) Activity Assay Kit addresses the need for quantitative, reproducible measurement of SOD enzyme activity in biological samples, supporting research in oxidative stress and antioxidative defense. It is best suited for laboratory-based applications in redox biology and should not be used for diagnostic or clinical decision-making.

• Molidustat (BAY85-3934): Integrating HIF Stabilization with

  2026-04-15

  Explore how Molidustat (BAY85-3934) advances renal anemia therapy via precise hypoxia-inducible factor stabilization, integrating new mechanistic insights on HIF-1α regulation. This article uniquely bridges molecular pharmacology and translational assay design, offering strategies not found in existing guides.

• CRM1 Inhibition Synergy in Triple-Negative Breast Cancer Mod

  2026-04-14

  This study systematically identified combination therapies involving nuclear export inhibition for triple-negative breast cancer (TNBC). KPT-330 (Selinexor), a selective CRM1 inhibitor, showed synergistic effects with a PI3K/mTOR inhibitor, resulting in significantly reduced tumor burden in preclinical basal-like TNBC models. These results highlight new therapeutic avenues for chemoresistant TNBC and inform protocol development in cancer research.

458 records 21/31 page Previous Next First page 上5页 2122232425 下5页 Last page